BMS Revenues Soar, But High-Flying Revlimid Is A Big Driver

First Generic Due In 2022; How Will Bristol Fill $12.1bn Gap?

 
• By Mandy Jackson

The Celgene acquisition gave BMS a new top-selling drug but Revlimid revenue will start to decline as soon as next year and it is likely to take many new products to replace it.

Airliner in flight
Revlimid generated $12.1bn in 2020 sales as Bristol's top-selling product • Source: Shutterstock

Bristol Myers Squibb Company’s fourth quarter and full year 2020 revenue beat analyst consensus, but the addition of Revlimid (lenalidomide) to the portfolio in late 2019 was a big contributor to last year’s growth. Since the first generic competition for the multiple myeloma blockbuster will emerge in 2022, BMS faced many questions during its 4 February earnings call about how the biopharmaceutical giant will fill the coming revenue gap.

In 2020 – the first full year of sales after the company closed its $74bn acquisition of Revlimid developer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 
• By Anju Ghangurde

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

US Tariff Overhang Weighs on Chinese API Exports

 
• By Dexter Jie Yan

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.